KB707

BIOLOGICAL3 trials

Sponsors

Krystal Biotech Inc., Krystal Biotech, Inc.

Conditions

Advanced CancerCancerCutaneous MelanomaLung Cancer (NSCLC)Lung Cancer MetastaticLung Cancer, Non-small CellMelanoma Stage IIIMelanoma Stage IV

Phase 1

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

RecruitingNCT05970497

Krystal Biotech, Inc.Cancer, Cutaneous Melanoma, Melanoma Stage III +1

Start: 2023-10-31End: 2027-07-31Target: 240Updated: 2025-05-18

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

RecruitingNCT06228326

Krystal Biotech, Inc.Advanced Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell +2

Start: 2024-04-17End: 2028-07-31Target: 250Updated: 2025-10-24

A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

Not yet recruitingCTIS2025-522723-98-00

Krystal Biotech Inc.solid tumor

Target: 20Updated: 2026-06-30

Related Papers

Inhaled delivery of KB707, a novel HSV-based immunotherapy, in combination with pembrolizumab in advanced non–small cell lung cancer: A phase 1/2 study.

Journal of Clinical Oncology2026-05-28

Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study.

Journal of Clinical Oncology2025-05-28